Figures 4A-F
(scroll down to see all figures)

 

Figure 4. Panel A
Beginning with the landmark 4S trial (panel A), HMG CoA reductase inhibitors have been proven to reduce the risk of death, myocardial infarction, and stroke in dyslipidemic patients. These findings have been repeatedly confirmed in large, prospective, placebo-controlled, randomized clinical trials such as the CARE (panel B), West of Scotland (panel C), LIPID (panel D), AFCAPS/TexCAPS (panel E), and most recently ASCOT (panel F) trials. For both patients with dyslipidemia but no previous cardiovascular event4,5 and for those dyslipidemic patients with established clinical CHD6-9 statin therapy is the bedrock of therapy.

 

Figure 4. Panel B

 

Figure 4. Panel C

 

Figure 4. Panel D

 

Figure 4. Panel E

 

Figure 4. Panel F